In recent years, several new targeted therapies have been introduced or are currently under investigation for aBC, such as cyclin-dependent kinase 4 and 6 (CDK4/6) and PI3K inhibitors for the treatment of HR+/HER2− aBC (Gennari et al. 2021). This evidence concerns the gene ERBB2 and aneurysmal bone cyst.